Cervical cancer in Uruguay. Controversies in prevention
Abstract
This review provides a critical analysis of the different cervical cancer prevention strategies, with an emphasis on immunization, implementation modalities, health strategies and national regulations.
Rather than favoring or opposing the obligation to observe health policies, the study aims to offer a critical discussion on the strategy.
It is often said that arguments in favor of the obligatory nature of a policy or recommendation are defined by two main axes: the first one refers to defining whether the population is facing a health risk in the population and the second one, whether informed decisions need to be promoted to achieve a larger impact. Thus, defining if addressing HPV infection within a comprehensive prevention strategy, as a sexually transmitted disease, is of paramount importance. To that end, the obligatory nature for all individuals involved in the epidemiological chain should be extensively discussed.
HPV vaccination is recommended in the framework of comprehensive educational programs, as in secondary, tertiary and quaternary prevention. Equality in terms of population protection against cervical cancer needs to be achieved, and in this respect the government needs to take responsibility for these actions and universal access to all strategies. In other words, equal access to vaccination is essential, as well as to other recommended prevention measures.
However, the need to refer to compulsory measures to stop avoidable deaths with measures we already know may be arguable, as this is a way to make up for failure to achieve other preventive measures, which have been demonstrated to reduce cervical cancer incidence and mortality.
References
(1) Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
(2) Barrios E, Garau M, Alonso R, Musetti C. IV Atlas de incidencia del cáncer en Uruguay 2007-2011. Montevideo: CHLCC, 2014.
(3) Barrios E, Musetti C, Alonso R, Garau M. V Atlas de mortalidad por cáncer en el Uruguay 2009-2013. Montevideo: CHLCC , 2015.
(4) zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977; 78:1-30.
(5) Papilomavirus humanos (PVH) y cáncer cervicouterino. Disponible en: Disponible en: http://www.who.int/mediacentre/factsheets/ fs380/es/ Consulta: 20 junio 2016
(6) Control integral del cáncer cervicouterino: guía de prácticas esenciales. 2a. ed. Washington, DC: OPS, 2016.
(7) Comisión Honoraria de Lucha contra el Cáncer. Programa de Prevención del Cáncer de Cuello Uterino “Dr. Enrique Pouey”- Resumen: 1994-2012. Disponible en: Disponible en: http://www.comisioncancer.org.uy/uc_137_1.html Consulta: 27 julio 2016
(8) Uruguay. Ministerio de Salud Pública. Vacuna contra el virus del papiloma humano. Disponible en: Disponible en: http://www.msp.gub.uy/sites/default/files/archivos_adjuntos/PAP-Gu%C3%ADa_para_t%C3%A9cnicos-2%281%29.pdf Consulta: 27 julio 2016
(9) Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1):12-9.
(10) de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
(11) Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30(Suppl. 5):F24-33.
(12) de Sanjosé S, Bosch FX, Muñoz N, Shah K. Social differences in sexual behaviour and cervical cancer. IARC Sci Publ 1997; (138):309-17.
(13) Berois N, De Cremoux P, Mazal D, Sica A, Cedeira M, Caserta B, et al. Prevalence and distribution of high-risk human papillomavirus genotypes in invasive carcinoma of the uterine cervix in Uruguay. Int J Gynecol Cancer. 2013; 23(3):527-32.
(14) Ríos-Romero M, Soto-Valladares A, Piña-Sánchez P. Alteraciones epigenéticas en la progresión del cáncer cervicouterino. Rev Med Inst Mex Seguro Soc 2015; 53(S2).
(15) Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4):683-92.
(16) Durzynska J, Lesniewicz K, Poreba E. Human papillomaviruses in epigenetic regulations. Mutat Res Rev Mutat Res 2016. Disponible en: Disponible en: http://dx.doi.org/10.1016/j.mrrev. 2016.09.006 Consulta: 14 abril 2016
(17) Diex Roux AV. Conceptual approaches to the study of health disparities. Annu Rev Public Health 2012; 33:41-58.
(18) Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009; 374:301-14.
(19) FUTURE I/II Study Group; Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ 2010; 341: c3493.
(20) Pagliusi S, Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23:569-78.
(21) Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; (4):204.
(22) Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women withHPV16/18 infection. Int J Cancer 2011; 129:2632-42.
(23) Vici P, Mariani L, Pizzuti L, Sergi D, Di Lauro L, Vizza E, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res 2014; 33: 29.
(24) Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep 2013; 62:591-5.
(25) Verweij M. Individual and collective considerations in public health: influenza vaccination in nursing homes. Bioethics 2001; 15:536-46.
(26) Garrett L, Chowdhury AM, Pablos-Méndez A. All for universal health coverage. Lancet 2009; 374(9697):1294-9. Disponible en: Disponible en: http://dx.doi.org/10.1016/S0140-6736(09)61503-8 . Consulta: 27 julio 2016
(27) Verweij MF, Houweling H. What is the responsibility of national government with respect vaccination? Vaccine 2014; 32:7163-6.
(28) Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137:516-42.
(29) American College of Obstetricians and Gynecologists. Announcements/New cervical cancer screening recommendations. Disponible en: Disponible en: http://www.acog.org/About_ACOG/ Consulta: 27 julio 2016
(30) Rigoni-Stern DA. Fatti statistici relativi alle malattie cancerose che servirono di base alle poche cose dette dal dott. G Servire Progr Pathol Tera 1842; 2:507-17.
(31) Alberts CJ, Vos RA, Borgdorff H, Vermeulen W, van Bergen J, Bruisten SM, et al. Vaginal high-risk human papillomavirus infection in a cross-sectional study among women of six different ethnicities in Amsterdam, the Netherlands: the HELIUS study. Sex Transm Infect 2016; 92(8):611-8.
(32) Paz-Zulueta M, Fernández-Feito A, Amparán Ruiz M, Azofra Olave A, Martín Seco Y, Ojugas Zabala S, et al. Prevalencia de genotipos del virus del papiloma humano de alto riesgo no vacunables dentro del programa de Detección Precoz de Cáncer de Cérvix en Cantabria. Aten Primaria 2016; 48(6):347-55.
